James Wymer

James Wymer, MD, FAAN

Professor

Department: MD-NEUROMUSCULAR NEUROLOGY
Business Phone: (352) 273-5550

About James Wymer

Dr. James Wymer is a neurologist and professor practicing at The University of Florida in Gainesville, Florida. He specializes in the diagnosis and management of neuromuscular diseases including amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease, muscles diseases and peripheral neuropathies. Dr. Wymer has an extensive experience in clinical research, and has been the principal investigator in numerous clinical trials including studies of ALS, diabetic neuropathy, multiple sclerosis, migraine headaches and epilepsy. He is a fellow of the American Academy of Neurology (AAN) and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). He is a member of several national consortiums to research neuropathic pain and ALS.

Dr. Wymer’s clinical interests include: • ALS or Lou Gehrig’s Disease • Neuromuscular diseases • Hereditary Neuropathy • Muscle disease • Multiple Sclerosis • Diabetic neuropathy • Migraine headaches • Neurofibromatosis

Board Certifications

  • Neurology
    American Board of Psychiatry and Neurology

Clinical Profile

Specialties
  • Neurology
Subspecialties
  • Neuromuscular Medicine
Areas of Interest
  • Amyotrophic lateral sclerosis (ALS)
  • Migraine
  • Multiple sclerosis
  • Neurofibromatosis 2
  • Neurofibromatosis-1
  • Neuromuscular disorders
  • Peripheral neuropathy

Research Profile

Areas of Interest
  • ALS
  • Muscular dystrophy
  • Neuropathy

Publications

2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 22(3-4):287-299 [DOI] 10.1080/21678421.2020.1822410. [PMID] 32969758.
2021
Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study.
Experimental neurology. 347 [DOI] 10.1016/j.expneurol.2021.113890. [PMID] 34624328.
2021
Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Muscle & nerve. 63(1):31-39 [DOI] 10.1002/mus.27091. [PMID] 33063909.
2021
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
JAMA neurology. 78(1):68-76 [DOI] 10.1001/jamaneurol.2020.2590. [PMID] 32809014.
2021
Reflexive Airway Sensorimotor Responses in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia. 36(4):574-582 [DOI] 10.1007/s00455-020-10171-6. [PMID] 32778945.
2021
Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.
Dysphagia. [DOI] 10.1007/s00455-021-10315-2. [PMID] 34037850.
2020
Clinical care and therapeutic trials in PLS.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 21(sup1):67-73 [DOI] 10.1080/21678421.2020.1837180. [PMID] 33602017.
2020
Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
PloS one. 15(8) [DOI] 10.1371/journal.pone.0236804. [PMID] 32790801.
2020
Preface: promoting research in PLS: current knowledge and future challenges.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 21(sup1):1-2 [DOI] 10.1080/21678421.2020.1840795. [PMID] 33602018.
2020
Sleep disorders in myotonic dystrophies.
Muscle & nerve. 62(3):309-320 [DOI] 10.1002/mus.26866. [PMID] 32212331.
2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
The New England journal of medicine. 383(10):919-930 [DOI] 10.1056/NEJMoa1916945. [PMID] 32877582.
2019
Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis.
Muscle & nerve. 59(5):531-536 [DOI] 10.1002/mus.26408. [PMID] 30620104.
2018
Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 19(3-4):311-312 [DOI] 10.1080/21678421.2017.1404109. [PMID] 29205054.
2018
Combined respiratory training in an individual with C9orf72 amyotrophic lateral sclerosis.
Annals of clinical and translational neurology. 5(9):1134-1138 [DOI] 10.1002/acn3.623. [PMID] 30250869.
2018
Targeting the Neuromuscular Junction in ALS.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 15(3):713-714 [DOI] 10.1007/s13311-018-0647-y. [PMID] 30006767.
2017
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 14(3):762-772 [DOI] 10.1007/s13311-016-0508-5. [PMID] 28070747.
2017
Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 14(3) [DOI] 10.1007/s13311-017-0517-z. [PMID] 28283968.
2017
Increasing Evidence for an Association Between Amyotrophic Lateral Sclerosis and Psychiatric Disorders.
JAMA neurology. 74(12):1396-1398 [DOI] 10.1001/jamaneurol.2017.1920. [PMID] 29049449.
2017
Paraneoplastic Lambert-Eaton Myasthenic Syndrome With Limbic Encephalitis: Clinical Correlation With the Coexistence of Anti-VGCC and Anti-GABAB Receptor Antibodies.
Journal of clinical neuromuscular disease. 19(2):84-88 [DOI] 10.1097/CND.0000000000000192. [PMID] 29189554.
2017
The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States.
Amyotrophic lateral sclerosis & frontotemporal degeneration. 18(5-6):351-357 [DOI] 10.1080/21678421.2017.1313868. [PMID] 28425762.
2015
Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.
Annals of clinical and translational neurology. 2(5):465-78 [DOI] 10.1002/acn3.186. [PMID] 26000320.
2014
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Current medical research and opinion. 30(11):2255-65 [DOI] 10.1185/03007995.2014.940040. [PMID] 25062507.
2011
Keratinocyte expression of calcitonin gene-related peptide β: implications for neuropathic and inflammatory pain mechanisms.
Pain. 152(9):2036-2051 [DOI] 10.1016/j.pain.2011.04.033. [PMID] 21641113.
2009
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
The Clinical journal of pain. 25(5):376-85 [DOI] 10.1097/AJP.0b013e318196d2b6. [PMID] 19454870.
2006
Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
Clinical therapeutics. 28(10):1607-18 [PMID] 17157116.
View on: PubMed
2006
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Annals of neurology. 59(5):780-7 [PMID] 16634036.
View on: PubMed

Grants

Jan 2020 ACTIVE
Quality of Life Grant MS Foundation
Role: Principal Investigator
Funding: MULTIPLE SCLEROSIS FOUNDATION
Jan 2020 – Jun 2020
Natural History Pilot Project- University of Florida
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Sep 2019 ACTIVE
Surveillance of muscular dystrophy in the Southeastern United States
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2017 ACTIVE
A Program to develop a research database for the study of abnormal cellular components in Myasthenia Gravis: Specimen banking and data registry
Role: Principal Investigator
Funding: UF FOUNDATION
Apr 2017 ACTIVE
Delineating Physiologic Mechanisms of Swallowing impairment and Decline in ALS
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS

Education

Medical Degree
1984-1991 · University of Maryland

Teaching Profile

Courses Taught
2021
PAS5020 Intro to Medicine 2
2021
MDC7800 Neurology Clerkship

Contact Details

Phones:
Business:
(352) 273-5550
Emails: